The study, led by Prasanth Viswanathan and colleagues, focused on a protein called myeloid cell leukemia-1, or MCL1. MCL1 belongs to a family of proteins that act as molecular bodyguards, blocking the self-destruct program known as apoptosis. It is an oncogene, meaning that when it is amplified or overactive it drives cancer, and tumors with high MCL1 levels are notoriously resistant to chemotherapy. Because of its clinical importance, MCL1 inhibitors are already being developed and tested in trials, making it an attractive target for drug designers. Previous work had shown that PEL cell lines, the laboratory models of this lymphoma, cannot survive without MCL1, but the details of how MCL1 protects these virus-transformed cells remained murky.

To dig deeper, the team turned to a systems biology approach, mapping the web of genetic interactions surrounding MCL1 in PEL cells. This unbiased strategy surfaced a surprise: MCL1 appeared to function in the same pathway as a protein called MARCHF5, a membrane-anchored E3 ubiquitin ligase residing in the mitochondria. MARCHF5 was not an obvious suspect. It is best known for maintaining mitochondrial homeostasis and for tuning antiviral signaling pathways, not for regulating apoptosis. The genetic interaction hinted, however, that the two proteins cooperate in keeping PEL cells alive, and the researchers set out to test that idea directly.

The first experiment was decisive. Using CRISPR gene editing, the team knocked out the MARCHF5 gene in PEL cell lines. Even though MCL1 was still present and functional, the loss of MARCHF5 triggered a significant increase in apoptosis. In other words, MCL1 alone was not enough to keep the cells alive; they also needed MARCHF5. This was a striking result because it established that a mitochondrial ubiquitin ligase, a protein class usually discussed in the context of mitochondrial quality control, plays an essential anti-apoptotic role in these virus-transformed tumor cells.

MARCHF5 is an enzyme, and enzymes can often be disabled by breaking their catalytic machinery. The researchers probed which activities of MARCHF5 were required for its survival function. Two features proved essential: its E3 ligase activity, the enzymatic ability to attach ubiquitin tags to target proteins, and its capacity to dimerize, or pair up with another MARCHF5 molecule. When either of these activities was disrupted, the protein could no longer protect PEL cells from apoptosis. This mechanistic detail matters because it suggests the survival function of MARCHF5 is not a passive structural role but an active enzymatic process, one that could in principle be targeted with drugs.

What was MARCHF5 actually doing? The clue came from an unexpected direction. When the researchers removed MARCHF5, or when they treated the cells with inhibitors of the 26S proteasome, the cellular machine that destroys ubiquitin-tagged proteins, one particular protein accumulated: NOXA. NOXA is a pro-apoptotic member of the same protein family as MCL1, and its job is essentially to antagonize MCL1 and push the cell toward self-destruction. Intriguingly, the levels of MCL1 itself did not change under these conditions. Instead, MARCHF5 appeared to be keeping NOXA in check, and without MARCHF5 the lethal signal built up unchecked.

The team then asked whether NOXA was truly the pro-apoptotic signal that MCL1 and MARCHF5 exist to neutralize. Several lines of evidence converged on that conclusion. Endogenous reciprocal co-immunoprecipitation experiments, which pull protein complexes out of cells without artificial tagging, showed that MARCHF5 and NOXA are found together in the same protein complex, consistent with a direct physical relationship. Even more telling, when the researchers knocked out the NOXA gene on its own, the PEL cells gained a fitness advantage, suggesting that NOXA exerts a constant, damaging pressure on these tumor cells that must be continuously suppressed for survival.

The most convincing test came from a genetic rescue experiment. If NOXA accumulation is the reason that MARCHF5-deficient cells die, then deleting NOXA should save them. That is exactly what the researchers observed: knocking out NOXA restored cell viability in PEL lines that had lost MARCHF5. Together, these experiments provide the mechanistic link that underlies the original genetic interaction between MCL1 and MARCHF5. The model that emerges is elegant: MARCHF5, using its ubiquitin ligase activity, induces the degradation of NOXA, the natural enemy of MCL1, thereby reinforcing MCL1’s pro-survival function and allowing the KSHV-transformed cells to evade apoptosis.

This finding adds a new layer to the biology of KSHV-associated malignancies. Primary effusion lymphoma arises when the virus reprograms B cells into rapidly proliferating, apoptosis-resistant tumor cells that typically grow as lymphomas in body cavities. The virus achieves this in part by manipulating the host cell’s apoptotic machinery, and the MCL1-MARCHF5 axis now appears to be a central node in that manipulation. The fact that both proteins are required, and that they act through a defined substrate, NOXA, gives researchers a clearer picture of the survival circuitry that these tumors depend on. It also raises the possibility that similar cooperation between MCL1 and mitochondrial ubiquitin ligases operates in other cancers where MCL1 is amplified.

From a therapeutic standpoint, the implications are considerable. MCL1 inhibitors are an active area of drug development precisely because MCL1 amplification drives chemoresistance in many cancers. The new work suggests that combination therapies targeting both MCL1 and MARCHF5, or approaches that prevent MARCHF5 from degrading NOXA, could be more effective than hitting either protein alone, since the two oncogenes reinforce each other’s function. Disabling MARCHF5’s ligase activity would strip away one of the defenses that keeps NOXA suppressed, potentially sensitizing tumor cells to MCL1 inhibition or to existing chemotherapy regimens. As the authors note, this newly appreciated interaction between the MCL1 and MARCHF5 oncogenes may prove useful in improving the design of combination therapies for KSHV malignancies, offering a rational strategy against a cancer that has so far proven difficult to treat.

Subject of Research: How the mitochondrial ubiquitin ligase MARCHF5 cooperates with MCL1 to inhibit apoptosis in KSHV-transformed primary effusion lymphoma cells

Article Title: The Mitochondrial ubiquitin ligase MARCHF5 cooperates with MCL1 to inhibit Apoptosis in KSHV-transformed primary effusion lymphoma cell lines

Article References: Viswanathan, P., Bersonda, J. R., Gill, J., Navarro, A., Farrar, A. C., Caldarera, T., Murphy, A., Dunham, D., Boehme, K. W., & Manzano, M. (2026). The mitochondrial ubiquitin ligase MARCHF5 cooperates with MCL1 to inhibit apoptosis in KSHV-transformed primary effusion lymphoma cell lines. PLOS Pathogens, 22(10), e1014665. https://doi.org/10.1371/journal.ppat.1014665

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014665

Keywords: KSHV, primary effusion lymphoma, MCL1, MARCHF5, NOXA, apoptosis, ubiquitin ligase, mitochondria, CRISPR, oncogene, viral oncology, combination therapy

The research, published in Annals of Hematology, took a direct approach to a question that has lingered at the edge of AML biology for years. Rather than inferring apoptotic behavior from broad molecular signatures, the team prospectively measured messenger RNA expression of apoptosis-related genes in bone marrow mononuclear cells from 90 patients with newly diagnosed AML. Every sample came from patients at the start of their treatment journey, before therapy could reshape the transcriptional landscape of their leukemia. That design choice matters, because it allowed the investigators to ask whether the apoptotic wiring present at diagnosis could predict what happened next — how long patients lived, how they responded to treatment, and whether their disease returned.

When the researchers clustered patients according to their apoptosis gene expression profiles, two biologically distinct groups emerged, and the differences between them were striking. The first cluster carried a transcriptional pattern that, on its surface, looked almost reassuring: relatively higher expression of the classic anti-apoptotic gene BCL2, the very gene targeted by one of modern hematology’s most celebrated drugs. The second cluster told a more complicated story. These patients showed coordinated upregulation of a battery of pro-apoptotic genes, including BCL2L11 (better known as BIM), BBC3 (PUMA), BID, BAD, BIK, and BAX — genes whose protein products are supposed to push cells toward self-destruction. At the same time, the cells appeared to shift their survival strategy away from BCL2 and toward alternative anti-apoptotic regulators, with increased expression of MCL1 and BCL2L1, which encodes the survival protein BCL-xL.

That combination — more pro-death genes, but a survival apparatus rebuilt around different guardians — might seem paradoxical, and the clinical outcomes made the paradox impossible to ignore. Patients in the second cluster had significantly inferior overall survival. The researchers also observed reduced expression of CASP3 and CASP7, the executioner caspases that carry out the final, irreversible steps of apoptosis, in this high-risk group. Lower levels of these molecular executioners, the authors suggest, may mean that even when the death signal is triggered, the cell’s machinery for completing the process runs less efficiently. In other words, the leukemic cells of Cluster 2 patients appeared to be shouting the commands for self-destruction while simultaneously dismantling the equipment needed to obey them.

The timing of the study gives its findings particular weight. The treatment of AML has been transformed in recent years by venetoclax, a BCL2 inhibitor that, when combined with the hypomethylating agent azacitidine — a regimen known as VenAza — has become a backbone of therapy for older patients and those unfit for intensive chemotherapy. Venetoclax works by neutralizing BCL2, removing one of the main shields that leukemic cells use to resist apoptosis. If a patient’s leukemia depends heavily on BCL2, the drug should work well. If the cells have quietly reorganized their survival machinery around MCL1 or BCL-xL, the drug’s leverage diminishes. The Lodz team’s data fit that logic with unsettling precision: among patients treated with venetoclax plus azacitidine, those in Cluster 2 demonstrated significantly shorter event-free survival.

The biological features of Cluster 2 help explain why. The researchers noted that this subgroup displayed a monocytic immunophenotype, a characteristic that previous studies had already associated with reduced sensitivity to BCL2-targeted therapy. Monocytic AML cells tend to rely more on MCL1 and other alternative survival proteins than on BCL2 itself, making venetoclax a less effective key for that particular lock. Combined with the transcriptional evidence of increased MCL1 and BCL-xL expression and diminished executioner caspase activity, the picture that emerges is of a leukemia subtype that is not merely more aggressive, but differently engineered — one whose apoptotic architecture is fundamentally less vulnerable to the therapies now widely deployed against it.

Then comes the study’s most provocative single finding. When the researchers examined individual genes rather than cluster-level patterns, one stood out: BIK. Higher BIK mRNA expression was associated with poorer survival and with a lack of response to venetoclax-azacitidine therapy, and the association held up as an independent prognostic marker. The paradox here is sharp. BIK is a pro-apoptotic gene, a member of the BH3-only family whose role is to help tip cells into death. Higher expression of a death-promoting gene should, intuitively, be good news. Instead, in this cohort, it flagged the patients most likely to fare badly. The authors highlight this paradoxical association explicitly, and it serves as a reminder that gene expression in cancer rarely obeys simple intuition — context, coordination, and the surrounding molecular machinery determine whether a signal means surrender or defiance.

Why might high BIK expression accompany worse outcomes? The study’s cluster-level data suggest a plausible framework. In Cluster 2, BIK is upregulated alongside a host of other pro-apoptotic genes as part of a broader transcriptional state, one in which the cell simultaneously bolsters alternative survival pathways through MCL1 and BCL-xL and dampens the caspase machinery that would finalize apoptosis. In that setting, elevated BIK may be less a weapon than a distress signal — a marker of a cellular state in which death pathways are chronically activated yet chronically thwarted. Cells locked in such a standoff may be under persistent stress, and stress-adapted leukemic cells are often the most difficult to eradicate. BIK expression, on this reading, is not causing the poor prognosis but faithfully reporting it, which is precisely what a good biomarker should do.

The clinical implications ripple outward in several directions. First, the study demonstrates that apoptosis-related gene expression, measured at diagnosis, defines clinically distinct AML subgroups — a finding that could eventually inform how patients are risk-stratified beyond the current arsenal of cytogenetic and mutation-based markers. Second, the link between Cluster 2 biology and shortened event-free survival on venetoclax-azacitidine raises the possibility that expression profiling of apoptotic genes could help identify, upfront, which patients are unlikely to benefit from the regimen and might be better served by alternative or combination strategies, including agents targeting MCL1 that are currently in development. Third, the independent prognostic value of BIK offers a concrete, testable candidate for prospective validation in larger and more diverse cohorts.

Cautious interpretation remains essential. The cohort comprised 90 patients treated at a single center, and the findings, while internally coherent, will need replication before they reshape clinical practice. The authors themselves frame the results as demonstrating that dysregulation of apoptosis-related gene expression defines clinically distinct subgroups and may contribute to differences in prognosis and therapeutic response — a claim about mechanism and association rather than a prescription for immediate changes in care. Yet the conceptual shift the study proposes is substantial. AML has traditionally been classified by the mutations its cells carry; this work argues that how those cells manage life and death — the balance of pro- and anti-apoptotic forces, the choice of survival protein, the integrity of the caspase execution machinery — is itself a meaningful axis of disease biology. If subsequent studies confirm the pattern, the humble measurement of apoptosis gene mRNA could become a routine part of the diagnostic conversation, and the paradoxical signal from BIK could stand as a symbol of how much remains to be learned about why some leukemias die on command and others simply will not.

Subject of Research: Apoptosis-related gene expression profiling in acute myeloid leukemia and its association with patient clustering, prognosis, and response to venetoclax-based therapy

Article Title: Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker

Article References: Strzałka, K., Strzałka, P., Jarych, D., Wiśnik, A., Mikulski, D., Kościelny, K., Czemerska, M., Zawlik, I., Wierzbowska, A., & Pluta, A. (2026). Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker. Annals of Hematology. https://doi.org/10.1007/s00277-026-07268-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07268-7

Keywords: acute myeloid leukemia, apoptosis, gene expression profiling, BIK, venetoclax, azacitidine, BCL2, MCL1, prognostic marker, drug resistance, caspases, hematology